IVD · Class A · MD5 License · MDR 2017 · 2026

Starting a Blood Collection Tube Manufacturing Business in India: A 2026 Guide

Everything you need to start a blood collection tube manufacturing business in India — tube types, raw materials, the step-by-step manufacturing process, CDSCO regulations, and the complete MD5 license application pathway.

Reading Time:9 minutes
Device Category:IVD · Class A
License Required:MD5 · Form MD3 · SLA
Quick Answer — For AI & Voice Search

Blood collection tubes are sterile in vitro diagnostic (IVD) containers used to collect, preserve, and transport blood samples for laboratory testing. Under CDSCO's MDR 2017 framework, they are classified as Class A IVD devices. Manufacturing blood collection tubes in India requires the CDSCO MD5 license, applied via Form MD3 through the SUGAM portal to the State Licensing Authority. Common tube types include EDTA (purple), Serum (red/yellow), Heparin (green), Fluoride (grey), and Sodium Citrate (blue) tubes. The manufacturing process spans eight stages from raw material preparation to sterilisation and quality control packaging.

In 2026, every diagnostic laboratory in India — from a district hospital pathology unit to a five-star private hospital's central lab — depends on a product most people never notice: the blood collection tube. Billions of these tubes are consumed globally each year. In India, the majority are still imported, primarily from China and Europe. That import dependence represents a manufacturing opportunity that domestic entrepreneurs and medical device companies are increasingly recognising.

Starting a blood collection tube manufacturing business in India is achievable, commercially compelling, and — with the right regulatory preparation — straightforward to license. The CDSCO regulatory pathway for Class A IVDs is among the most accessible in India's medical device framework. What separates the manufacturers who launch efficiently from those who encounter delays is almost always the same thing: understanding the regulatory requirements before committing to the facility, the equipment, and the capital expenditure.

What This Guide Covers This is your complete 2026 reference for starting a blood collection tube manufacturing business in India — what these tubes are and why precision matters, the five main tube types, raw materials and their functions, the 8-step manufacturing process, and the complete CDSCO regulatory pathway including IVD classification, the MD5 license, document checklist, and the 8-step SUGAM application process.

What Are Blood Collection Tubes?

Blood collection tubes are sterile, sealed containers designed to collect blood samples directly from a patient's vein, preserve those samples in a defined chemical environment, and transport them to a laboratory for analysis. They are manufactured under controlled conditions to ensure sterility, maintain accurate vacuum levels for consistent blood draw volumes, and deliver additive formulations precisely matched to the tests the collected blood will undergo.

The tubes are manufactured in standardised sizes and identified by colour-coded caps — a globally recognised system that tells laboratory technicians at a glance which additive the tube contains and which tests it is suited for. Accuracy in manufacturing each element of the tube — the body material, the stopper, the vacuum, and above all the additive — directly determines the accuracy of the diagnostic results produced from blood collected in it.

Market Opportunity in India 2026

₹2,800Cr+
Estimated Indian blood collection tube market in 2026, growing at 10–13% annually
60–70%
Import dependence — majority of tubes currently sourced from China and Europe
Recurring
High-frequency consumable product — every diagnostic test requires new tubes, driving reliable recurring revenue
Why Domestic Manufacturing Makes Commercial Sense Blood collection tubes are consumed in enormous volumes — hospitals, clinics, diagnostic chains, and blood banks all require continuous restocking. India's expanding diagnostic infrastructure, driven by insurance coverage growth, Ayushman Bharat, and the post-pandemic rise in preventive health testing, is increasing tube consumption at a rate that domestic supply has not kept pace with. Manufacturers who establish a quality-certified domestic production unit benefit from lower logistics costs, shorter supply chains, and growing preference among hospital procurement teams for locally certified suppliers with faster delivery and local quality accountability.

Why Precision Is Critical in Blood Collection Tube Manufacturing

Blood collection tubes are unlike most manufactured products in one critical respect: their quality cannot be verified by the end user. A hospital laboratory technician drawing blood from a patient trusts that the tube's vacuum level is accurate, the additive formulation is correct, the stopper creates a perfect seal, and the interior is sterile. None of these properties are visible. None can be tested quickly at point of use. They are either built correctly during manufacturing — or they are not.

Even minor deviations have serious consequences. An additive underdose in an EDTA tube can cause clotting, making the sample unusable and requiring the patient to undergo an additional draw. A vacuum that is slightly too low delivers an insufficient blood volume, compromising the test result. A contaminated interior can introduce false positives across an entire batch. Because blood collection tube outputs directly influence clinical diagnosis and treatment decisions — including whether a patient receives a specific medication, undergoes surgery, or is sent for further investigation — the quality requirements for these products are among the most stringent in the Class A IVD category.

Common Blood Collection Tube Types

Different laboratory tests require different blood sample conditions — some tests need anticoagulated whole blood, others require serum, others require plasma with specific preservatives. Blood collection tubes are designed to deliver precisely the sample condition each test requires, through the specific additive formulation pre-loaded into each tube type.

🟣
EDTA Tube
Haematology testing — CBC, blood cell counts
🟡
Serum Tube
Biochemistry — clot activator or gel separator
🟢
Heparin Tube
Plasma-based tests — electrolytes, trace elements
Fluoride Tube
Glucose testing — preserves blood glucose levels
🔵
Sodium Citrate Tube
Coagulation studies — PT, APTT testing

Each tube type requires a precisely formulated and accurately dosed additive — EDTA, heparin, sodium citrate, sodium fluoride, or gel-based clot activator — along with specific manufacturing parameters for vacuum level, stopper composition, and tube body surface treatment. Manufacturers who produce multiple tube types must demonstrate that their facility and quality systems can maintain the required precision across each product independently.

Raw Materials Used in Manufacturing

🧴
PET (Polyethylene Terephthalate)

The primary material for tube bodies in modern manufacturing. PET is lightweight, durable, shatter-resistant, and compatible with blood chemistry. It has largely replaced glass as the preferred tube body material due to improved safety for laboratory personnel and cost-effectiveness in high-volume production. Medical-grade PET must meet specific optical clarity and chemical inertness standards.

🔬
Glass Tube Bodies

Still used in specialised applications where the chemical inertness of borosilicate glass is required — particularly for certain trace element or heavy metal assay tubes where PET surface interactions could introduce contamination. Glass manufacturing requires additional investment in safety engineering and breakage management, but serves specific high-value test categories where PET is not suitable.

🔴
Rubber Stoppers

The coloured, air-tight stoppers that seal the tube and maintain vacuum. Stopper formulation is critical — the rubber compound must be chemically compatible with the tube's additive, must maintain a consistent gas-tight seal under storage and transport conditions, and must allow needle penetration without coring (releasing rubber fragments into the sample). Stopper colour codes follow standardised international conventions.

⚗️
Chemical Additives

The functional heart of every tube type. EDTA (K2 or K3) for haematology, lithium or sodium heparin for plasma tubes, trisodium citrate at precise ratios for coagulation tubes, sodium fluoride for glucose preservation, and silica or thrombin-based clot activators for serum tubes. Each additive must be sourced to pharmaceutical-grade specifications and dosed with high precision — typically ±2% of the target concentration.

🛡️
Silicone Coating

Applied to the interior wall of tube bodies to prevent blood cells from adhering to the surface — which would introduce systematic errors into cell count tests and affect sample recovery. Silicone coating must be applied uniformly and validated to remain stable throughout the tube's stated shelf life without leaching into the sample.

🏷️
Labels and Colour-Coded Caps

Labels must carry all required information under MDR 2017 labelling requirements — lot number, expiry date, additive type, tube volume, manufacturer details — and must be resistant to smearing in laboratory environments. Colour-coded caps must match international conventions for the additive they identify, and must be manufactured to tolerance specifications that ensure consistent stopper seating and vacuum retention.

8-Step Blood Collection Tube Manufacturing Process

Blood collection tube manufacturing requires a controlled, sequential process in which each stage builds on the precision of the previous one. The following eight stages describe the complete production pathway from raw materials to finished, certified, packaged product.

1
Raw material preparation and verification

All incoming materials — PET granules, glass tubing, rubber stoppers, chemical additives, silicone, labels, and caps — are inspected and verified against specifications before entering production. Medical-grade PET or glass for tube bodies is confirmed against optical clarity, chemical purity, and dimensional tolerance specifications. Chemical additives are verified against Certificate of Analysis from the supplier and subjected to incoming QC testing to confirm concentration and identity before use in production.

2
Tube body moulding

PET granules are heated and injection-moulded into cylindrical tube bodies under controlled temperature and pressure conditions. Wall thickness uniformity is critical — variation across the tube wall affects vacuum retention and structural integrity. Each tube body is inspected for dimensional conformance, surface defects, and optical clarity immediately after moulding, before advancing to downstream processing.

3
Silicone coating

The interior surface of each tube body is coated with medical-grade silicone using automated coating equipment. Coating uniformity is verified by gravimetric measurement and visual inspection. Coated tubes are subjected to a curing process to stabilise the silicone layer before additive introduction. Inadequate or uneven coating is detected and rejected before any additive is introduced into the tube.

4
Additive dosing

Chemical additives — EDTA, heparin, citrate, fluoride, or clot activator, depending on tube type — are introduced into each tube in precisely controlled amounts using automated dosing equipment. Dosing accuracy is validated to ±2% of the target concentration. Liquid additives are dispensed volumetrically; powder additives by weight or spray-drying. The sterile production environment is maintained throughout this stage to prevent contamination of the tube interior.

5
Stopper and cap assembly

Colour-coded rubber stoppers are fitted to each tube under controlled vacuum conditions. The stopper must create a gas-tight seal that maintains the target vacuum throughout the product's stated shelf life. After stopper insertion, colour-coded outer caps are applied and checked for correct seating. Assembly is performed in a cleanroom environment to prevent particulate or microbial contamination of the sealed tube.

6
Vacuum calibration and integrity testing

The vacuum level within each sealed tube is calibrated using automated pressure measurement equipment. The target vacuum is determined by the tube's stated fill volume — the vacuum must draw precisely that volume of blood when the tube is used with a standard needle and holder. Tubes outside the vacuum tolerance are rejected. Vacuum integrity is also tested over time as part of stability validation to confirm the seal remains effective throughout shelf life.

7
Sterilisation

Blood collection tubes are sterilised using gamma irradiation or ethylene oxide (ETO) sterilisation, depending on the tube's material composition and additive chemistry. The sterilisation cycle is validated to achieve a sterility assurance level (SAL) of 10⁻⁶. Sterilisation validation records and routine biological indicator testing are maintained as part of the quality management system and are available for CDSCO review during facility inspection.

8
Quality control and packaging

Each finished batch undergoes a complete quality control programme — dimensional inspection, additive concentration verification by validated analytical method, vacuum retention testing, sterility testing of representative samples, and label verification. Tubes that pass all QC checks are packaged in sterile, tamper-evident secondary packaging with outer carton labelling meeting MDR 2017 Schedule IV requirements. Batch records are completed and reviewed before the batch is released for distribution.

CDSCO Regulations for Blood Collection Tube Manufacturing

Blood collection tubes are regulated by CDSCO as in vitro diagnostic (IVD) devices under the Medical Devices Rules, 2017. This classification reflects the direct relationship between tube performance and diagnostic accuracy — a tube that contaminates, dilutes, or chemically alters the blood sample it collects directly affects the reliability of laboratory results that clinicians use for patient care decisions.

Regulatory Parameter Blood Collection Tube Status
Device categoryIn vitro diagnostic device (IVD)
CDSCO risk classClass A — low risk IVD
Classification basisUsed to collect and preserve blood for ex-vivo laboratory analysis; does not enter or contact the body directly in a sustained manner
Manufacturing license requiredMD5 — applied via Form MD3 to the State Licensing Authority
Loan license optionMD6 — applied via Form MD4 for manufacturers without own facility
Import license requiredMD15 — applied via Form MD14 to the Central Licensing Authority
Regulatory frameworkMedical Devices Rules, 2017 (MDR 2017) — IVD provisions
Issuing authority (manufacture)State Licensing Authority of the manufacturer's state
Why Class A — Not Class B or C? CDSCO classifies blood collection tubes as Class A IVDs because the tube itself does not directly diagnose disease — it collects and preserves a blood sample for analysis by a separate laboratory instrument. The analytical risk is attributed to the laboratory analyser, not the collection container. However, Class A does not mean regulatory-light: blood collection tubes are still notified IVD products under MDR 2017 and require a full CDSCO manufacturing license, ISO 13485 certification, and complete technical documentation before commercial production can begin.

Document Checklist for CDSCO Blood Collection Tube Manufacturing License

The MD5 application for blood collection tube manufacturing requires a complete technical dossier. Every document below must be current, complete, and internally consistent before you open the SUGAM portal.

  • Cover letter addressed to the State Licensing Authority with complete applicant and device details
  • Organisation identity proof — UDYAM Aadhaar, PAN card, or equivalent
  • Constitution proof — GST Certificate, Certificate of Incorporation (CIN), Memorandum and Articles of Association (MOA/AOA)
  • Sale Deed or Rent/Lease Deed proving legal occupation of the manufacturing premises
  • Plant Master File (PMF) — complete description of the manufacturing facility, infrastructure, environmental controls, QMS overview, and GMP compliance
  • Device Master File (DMF) — complete technical specifications, intended use, manufacturing process, additive formulations, bill of materials, risk analysis, and quality control data for each blood collection tube type
  • Certificate of Analysis for 3 consecutive production batches — demonstrating that additive concentration, vacuum level, sterility, and dimensional parameters meet specifications under actual manufacturing conditions
  • Dimensioned building layout plan — room-by-room drawings showing equipment locations, cleanroom classifications, material flow, and personnel flow
  • Personnel qualification documents — educational qualifications, relevant experience, and training records for manufacturing and quality control personnel
  • Test License (if applicable) — for manufacturing small quantities of blood collection tubes for testing or validation purposes prior to commercial production
  • ISO 13485 certificate — valid, in-scope for IVD manufacturing, issued by an accredited certification body
  • Fire NOC — from the local fire authority
  • Pollution NOC — from the state pollution control board

8-Step CDSCO License Application Process for Blood Collection Tube Manufacturing

Here is the complete process from portal registration through to license receipt, with the actions at each stage that determine whether your application moves efficiently or generates delays.

1
Portal login

Create or sign in to your account on the CDSCO SUGAM portal at cdscoonline.gov.in. Verify your contact details and account access before beginning the application. Portal access issues discovered on submission day can add unnecessary delays to an otherwise ready application.

2
Form MD3 completion

Fill the Form MD3 application for Class A IVD manufacturing license. Every field — device classification, product name, intended use, additive type, manufacturer details, and facility address — must be completed accurately and must match supporting documents exactly. Discrepancies between Form MD3 and supporting documents are the most common cause of immediate SLA queries for blood collection tube applications.

3
Document submission

Upload all required supporting documents through SUGAM in the correct format and naming convention. Check file sizes against SUGAM's upload limits before attempting submission. Confirm that ISO 13485 certificate scope explicitly covers IVD manufacturing and that the Certificate of Analysis covers the blood collection tube types listed in your Form MD3 application.

4
Fee payment

Pay the prescribed CDSCO application fee for a Class A IVD manufacturing license through the SUGAM portal. Payment is made digitally and must be completed before the application can be formally submitted. Retain the digital payment receipt as part of your application records.

5
Application review

The State Licensing Authority reviews your application and all submitted documents. For Class A IVD products, the review assesses documentation completeness, ISO 13485 scope alignment, and the technical adequacy of the Device Master File for the specific blood collection tube types applied for. Monitor your SUGAM application status actively during this period.

6
CDSCO queries

The SLA may raise queries requesting clarification or additional documents. Common query topics for blood collection tube applications include: ISO 13485 scope confirmation for IVD manufacturing, additive formulation details in the Device Master File, and batch Certificate of Analysis coverage. Respond to every query promptly, completely, and with supporting evidence. Each day of delayed response extends your overall timeline.

7
Facility inspection

The SLA may conduct an on-site inspection of your manufacturing facility, particularly for sterile IVD products where cleanroom conditions and sterilisation validation are critical. If inspection is scheduled, ensure your Plant Master File accurately reflects the facility as it exists — inspectors cross-check physical conditions against documented descriptions. Run a pre-inspection internal walk-through before the SLA visit.

8
License grant

Once all criteria are satisfied, the State Licensing Authority grants the MD5 license for blood collection tube manufacturing. Verify all details — facility address, tube types listed, IVD class, and license number — against your application before commencing commercial production. File the original license securely and display a certified copy at your facility as required.

Frequently Asked Questions

Does each blood collection tube type need a separate CDSCO license?

No. A single MD5 license can cover multiple blood collection tube types manufactured at the same facility, provided each tube type is included in the Form MD3 application and the Device Master File contains product-specific specifications and formulation data for each type. Adding new tube types after the initial license is granted requires a variation application to the State Licensing Authority — not a fresh license application.

Can I manufacture blood collection tubes without my own facility using a loan license?

Yes. CDSCO provides the MD6 loan license (applied via Form MD4) for manufacturers who intend to use another licensed IVD manufacturer's facility. The loan license requires a consent letter from the principal manufacturing unit, the principal manufacturer's MD5 license and product permit, and your own wholesale license as the applicant. The product is manufactured under your brand at the principal facility, under your loan license.

Is ISO 13485 mandatory for blood collection tube manufacturing?

Yes. ISO 13485 certification is mandatory for all CDSCO MD5 IVD manufacturing license applications, including blood collection tubes. The certificate must be valid, issued by an accredited certification body, and its scope must explicitly cover in vitro diagnostic device manufacturing. A certificate scoped to general medical device manufacturing that does not reference IVD products will generate an SLA query.

What sterilisation methods are acceptable for blood collection tubes under CDSCO?

CDSCO accepts gamma irradiation and ethylene oxide (ETO) sterilisation as validated methods for blood collection tube sterilisation, subject to sterilisation validation documentation demonstrating achievement of a sterility assurance level of 10⁻⁶. The choice of method must be justified in the Device Master File based on compatibility with the tube's materials and additives, and the sterilisation validation records must be available for SLA review.

✓ Key Takeaways

  • Blood collection tubes are classified as Class A in vitro diagnostic (IVD) devices under CDSCO MDR 2017 — because they collect and preserve blood for ex-vivo analysis rather than directly contacting the body in a sustained manner
  • Manufacturing blood collection tubes in India requires the CDSCO MD5 license, applied via Form MD3 on the SUGAM portal to the State Licensing Authority
  • Common tube types — EDTA (purple), Serum (red/yellow), Heparin (green), Fluoride (grey), and Sodium Citrate (blue) — can all be covered under a single MD5 license if included in the Form MD3 application with device-specific DMF documentation
  • Precision in additive dosing (±2%), vacuum calibration, and sterilisation is critical — even minor manufacturing deviations can compromise diagnostic accuracy and patient safety
  • The 8-step manufacturing process spans raw material verification, tube moulding, silicone coating, additive dosing, stopper assembly, vacuum calibration, sterilisation, and QC packaging
  • A loan license (MD6, Form MD4) is available for brand owners without their own manufacturing facility — requiring consent from a licensed principal manufacturer
  • India's blood collection tube market is large, growing, and significantly import-dependent — domestic manufacturers benefit from lower logistics costs, faster supply, and preference among procurement teams for CDSCO-certified local suppliers
  • Begin ISO 13485 certification and documentation preparation before committing to facility capital expenditure — regulatory timelines should be built into your business plan from day one

Your Next Step

Starting a blood collection tube manufacturing business in India is a commercially well-founded decision in 2026. The market is large, structurally dependent on imports that domestic manufacturers can competitively replace, and driven by healthcare infrastructure trends that show no sign of decelerating. The regulatory pathway — a Class A IVD MD5 license — is among the most accessible in India's medical device framework.

The manufacturers who launch efficiently are those who understand the regulatory requirements before they commit to their facility design. ISO 13485 certification, cleanroom infrastructure for sterile IVD manufacturing, sterilisation validation, and additive formulation quality systems all take time to establish. Plan them into your project timeline from the outset — not as afterthoughts once the equipment is installed.

Speak to a Rego Services regulatory consultant today to map your blood collection tube manufacturing license pathway, confirm your documentation requirements, and build a regulatory timeline that matches your business plan.

📅 Last Updated: June 2026  |  ✓ Regulatory Status: Current  |  Source: CDSCO MDR 2017 & 2026 SLA Guidelines  |  Published by Rego Services Private Limited